Monday, December 21, 2009

FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients

|More|
Friday, July 31, 2009

Ferring donates $3 million to the Royal Textile Academy of Bhutan

|More|
Tuesday, June 30, 2009

Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2010 Theme Announced

|More|
Tuesday, June 30, 2009

New Data Supports Significant Economic and Clinical Value of MENOPUR® in IVF

|More|
Tuesday, June 30, 2009

Ferring launches New International Fertility Media Award (FIMA) 2010

|More|
Thursday, April 02, 2009

Ferring Pharmaceuticals announces new Board Member

|More|
Wednesday, March 25, 2009

Frost & Sullivan Accolade for Ferring Pharmaceuticals

|More|
Wednesday, March 18, 2009

FIRMAGON® (degarelix) is launched in Europe for the treatment of advanced prostate cancer

|More|
Thursday, February 19, 2009

Ferring Pharmaceuticals creates Executive Board

|More|
Thursday, February 19, 2009

European Commission grants Ferring Pharmaceuticals approval of FIRMAGON® (degarelix) for treatment of prostate cancer

|More|
Thursday, January 22, 2009

Ferring Pharmaceuticals donates $1 million to McGill University

|More|
Thursday, January 22, 2009

Ferring Pharmaceuticals fait un don d’1 million à l’université McGill

|More|
 

By using the service, you agree to the following:

Your email address and the recipient's email address will be used for transmission purposes only - to inform the addressee about the sender, or for sending a message in the event of a transmission error. Both email addresses will be deleted from our system after a short period.